

Inge Skilde Pedersen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7134625/inge-sokilde-pedersen-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

76
papers

2,637
citations

26
h-index

50
g-index

81
ext. papers

3,439
ext. citations

6.5
avg, IF

3.62
L-index

#	Paper	IF	Citations
76	Cancer Risks Associated With and Pathogenic Variants.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102112	2.2	7
75	Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants.. <i>Genetics in Medicine</i> , 2021 ,	8.1	2
74	DNA Methylation Changes in Fibromyalgia Suggest the Role of the Immune-Inflammatory Response and Central Sensitization. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
73	DNA methylation changes in genes involved in inflammation and depression in fibromyalgia: a pilot study. <i>Scandinavian Journal of Pain</i> , 2021 , 21, 372-383	1.9	3
72	Cell-based non-invasive prenatal testing for monogenic disorders: confirmation of unaffected fetuses following preimplantation genetic testing. <i>Journal of Assisted Reproduction and Genetics</i> , 2021 , 38, 1959-1970	3.4	3
71	The mutational profile of immune surveillance genes in diagnostic and refractory/relapsed DLBCLs. <i>BMC Cancer</i> , 2021 , 21, 829	4.8	
70	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. <i>Nature Communications</i> , 2021 , 12, 1078	17.4	4
69	Dysfibrinogenemia-Potential Impact of Genotype on Thrombosis or Bleeding. <i>Seminars in Thrombosis and Hemostasis</i> , 2021 ,	5.3	1
68	Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	3
67	Prevalence and type distribution of human papillomavirus infections in Danish patients diagnosed with vulvar squamous cell tumors and precursors. <i>Gynecologic Oncology Reports</i> , 2021 , 37, 100828	1.3	0
66	A family-based study to identify genetic biomarkers of fibromyalgia: consideration of patientsQ subgroups. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39 Suppl 130, 144-152	2.2	
65	Epigenetic Regulation of Ferroportin in Primary Cultures of the Rat Blood-Brain Barrier. <i>Molecular Neurobiology</i> , 2020 , 57, 3526-3539	6.2	2
64	Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). <i>JAMA Oncology</i> , 2020 , 6, 1218-1230	13.4	25
63	Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. <i>Genetic Epidemiology</i> , 2020 , 44, 442-468	2.6	9
62	A systematic review on concurrent aneuploidy screening and preimplantation genetic testing for hereditary disorders: What is the prevalence of aneuploidy and is there a clinical effect from aneuploidy screening?. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2020 , 99, 696-706	3.8	2
61	Development of a Precision Medicine Workflow in Hematological Cancers, Aalborg University Hospital, Denmark. <i>Cancers</i> , 2020 , 12,	6.6	6
60	Association of Genomic Domains in and with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020 , 80, 624-638	10.1	22

59	DNA methylation biomarkers in peripheral blood of patients with head and neck squamous cell carcinomas. A systematic review. <i>PLoS ONE</i> , 2020 , 15, e0244101	3.7	2
58	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020 , 52, 56-73	36.3	56
57	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. <i>Genetics in Medicine</i> , 2020 , 22, 1653-1666	8.1	34
56	Use of genetic testing for hypolactasia trait in the North Denmark Region. <i>Scandinavian Journal of Gastroenterology</i> , 2020 , 55, 1012-1018	2.4	0
55	Association of germline variation with the survival of women with pathogenic variants and breast cancer. <i>Npj Breast Cancer</i> , 2020 , 6, 44	7.8	3
54	Mutational landscape of immune surveillance genes in diffuse large B-cell lymphoma. <i>Expert Review of Hematology</i> , 2020 , 13, 655-668	2.8	3
53	Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. <i>Human Mutation</i> , 2019 , 40, 1557-1578	4.7	52
52	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. <i>Nature Communications</i> , 2019 , 10, 1741	17.4	47
51	Mitochondrial Disease Caused by a Novel Homozygous Mutation (Gly106del) in the SCO1 Gene. <i>Neonatology</i> , 2019 , 116, 290-294	4	5
50	Whole-exome sequencing identifies a GREB1L variant in a three-generation family with Müllerian and renal agenesis: a novel candidate gene in Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome. A case report. <i>Human Reproduction</i> , 2019 , 34, 1838-1846	5.7	17
49	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. <i>Human Mutation</i> , 2018 , 39, 593-620	4.7	138
48	The c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium. <i>Journal of Medical Genetics</i> , 2018 , 55, 15-20	5.8	36
47	Full in-frame exon 3 skipping of confers high risk of breast and/or ovarian cancer. <i>Oncotarget</i> , 2018 , 9, 17334-17348	3.3	13
46	Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG. <i>Acta Oncologica</i> , 2018 , 57, 95-101	3.2	12
45	A Danish national effort of BRCA1/2 variant classification. <i>Acta Oncologica</i> , 2018 , 57, 159-162	3.2	2
44	Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and Breast/Ovarian) Cancer Susceptibility Genes: An International Survey by the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working Group. <i>JCO Precision Oncology</i> , 2018 , 2,	3.6	12
43	Differential effect of surgical manipulation on gene expression in normal breast tissue and breast tumor tissue. <i>Molecular Medicine</i> , 2018 , 24, 57	6.2	3
42	The prognostic efficacy of cell-free DNA hypermethylation in colorectal cancer. <i>Oncotarget</i> , 2018 , 9, 7010-7022	3.3	11

41	Clinical outcomes of female breast cancer according to BRCA mutation status. <i>Cancer Epidemiology</i> , 2017 , 49, 128-137	2.8	5
40	De novo Mutation Identified with Whole-Exome Sequencing in a Girl with Say-Barber/Biesecker/Young-Simpson Syndrome. <i>Molecular Syndromology</i> , 2017 , 8, 24-29	1.5	4
39	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017 , 49, 680-691	36.3	190
38	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017 , 49, 1767-1778	36.3	186
37	Hypermethylated DNA, a circulating biomarker for colorectal cancer detection. <i>PLoS ONE</i> , 2017 , 12, e0180809	4.9	45
36	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2240-2250	2.2	101
35	Promoter hypermethylation in plasma-derived cell-free DNA as a prognostic marker for pancreatic adenocarcinoma staging. <i>International Journal of Cancer</i> , 2017 , 141, 2489-2497	7.5	17
34	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. <i>Breast Cancer Research and Treatment</i> , 2017 , 161, 117-134	4.4	15
33	Cell-free DNA promoter hypermethylation in plasma as a predictive marker for survival of patients with pancreatic adenocarcinoma. <i>Oncotarget</i> , 2017 , 8, 93942-93956	3.3	23
32	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016 , 141, 386-401	4.9	15
31	BRCA1/BRCA2 founder mutations and cancer risks: impact in the western Danish population. <i>Familial Cancer</i> , 2016 , 15, 507-12	3	8
30	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	65
29	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>PLoS ONE</i> , 2016 , 11, e0158801	3.7	7
28	Hypermethylated DNA as a biomarker for colorectal cancer: a systematic review. <i>Colorectal Disease</i> , 2016 , 18, 549-61	2.1	41
27	Cell-free DNA promoter hypermethylation in plasma as a diagnostic marker for pancreatic adenocarcinoma. <i>Clinical Epigenetics</i> , 2016 , 8, 117	7.7	45
26	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , 2016 , 18, 15	8.3	58
25	ECEL1 mutation causes fetal arthrogyrosis multiplex congenita. <i>American Journal of Medical Genetics, Part A</i> , 2015 , 167A, 731-43	2.5	23
24	Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 1347-61	27.4	286

23	Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 308-16	4	20
22	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2015 , 17, 61	8.3	16
21	The PHF6 Mutation c.1A>G; pM1V Causes Björson-Forsman-Lehmann Syndrome in a Family with Four Affected Young Boys. <i>Molecular Syndromology</i> , 2015 , 6, 181-6	1.5	4
20	Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. <i>PLoS ONE</i> , 2015 , 10, e0120020	3.7	26
19	Comparison of mRNA splicing assay protocols across multiple laboratories: recommendations for best practice in standardized clinical testing. <i>Clinical Chemistry</i> , 2014 , 60, 341-52	5.5	53
18	DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. <i>PLoS Genetics</i> , 2014 , 10, e1004256	6	33
17	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2014 , 16, 3416	8.3	46
16	COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration. <i>Breast Cancer Research</i> , 2013 , 15, 402	8.3	30
15	Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. <i>PLoS Genetics</i> , 2013 , 9, e1003212	6	209
14	High recovery of cell-free methylated DNA based on a rapid bisulfite-treatment protocol. <i>BMC Molecular Biology</i> , 2012 , 13, 12	4.5	16
13	ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. <i>Human Mutation</i> , 2012 , 33, 2-7	4.7	211
12	Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members. <i>Breast Cancer Research and Treatment</i> , 2012 , 132, 1009-23	4.4	51
11	Common polymorphisms in the microsomal epoxide hydrolase and N-acetyltransferase 2 genes in association with inflammatory bowel disease in the Danish population. <i>European Journal of Gastroenterology and Hepatology</i> , 2011 , 23, 269-74	2.2	4
10	A BRCA2 mutation incorrectly mapped in the original BRCA2 reference sequence, is a common West Danish founder mutation disrupting mRNA splicing. <i>Breast Cancer Research and Treatment</i> , 2011 , 128, 179-85	4.4	4
9	Genetic variants of glutathione S-transferases mu, theta, and pi display no susceptibility to inflammatory bowel disease in the Danish population. <i>Scandinavian Journal of Gastroenterology</i> , 2010 , 45, 1068-75	2.4	10
8	BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer. <i>Acta Oncologica</i> , 2008 , 47, 772-7	3.2	40
7	Mutations in CARD15 and smoking confer susceptibility to Crohn's disease in the Danish population. <i>Scandinavian Journal of Gastroenterology</i> , 2007 , 42, 1445-51	2.4	24
6	Serological and molecular evidence of <i>Rickettsia helvetica</i> in Denmark. <i>Scandinavian Journal of Infectious Diseases</i> , 2004 , 36, 559-63		53

5	Promoter switch: a novel mechanism causing biallelic PEG1/MEST expression in invasive breast cancer. <i>Human Molecular Genetics</i> , 2002 , 11, 1449-53	5.6	39
4	The MAS proto-oncogene is imprinted in human breast tissue. <i>Genomics</i> , 1997 , 46, 509-12	4.3	21
3	Biallelic expression of the IGF2 gene in human breast disease. <i>Human Molecular Genetics</i> , 1996 , 5, 1123-7	5.6	48
2	Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk		1
1	Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes		2